European small-cap stocks - a segment characterized by attractive valuations and strong recovery potential. This product meets the growing demand for European investments and strengthens Strivo’s position in the market.
For several years, European small-cap stocks have been underrepresented, with large-cap companies outpacing them in both capital flows and returns. However, the segment is now presenting an appealing opportunity, with small-cap stocks trading at a discount. Thanks to a shift in the macroeconomic environment, a more stable interest rate outlook, and improved investor risk appetite, European small-cap stocks are well-positioned for recovery.
Increased focus on Europe, particularly in infrastructure, combined with a shift in global capital flows towards European markets, further enhances the outlook for the segment.
The European market offers a diverse range of small-cap stocks, creating an exciting landscape for investors. Through this tracker certificate, Strivo now provides access to small-cap stocks on developed European markets, employing a strategy designed to identify undervalued stocks with growth potential, stable margins, and predictable cash flows.
This new offering broadens Strivo’s global investment options, providing investors with a unique opportunity to tap into European small-cap stocks with a focus on net pricing and transparency.
Read more here.
Strivo launches a new tracker certificate providing exposure to the global pharmaceutical sector in connection with issuance 2026:1. The tracker certificate offers investors access to a sector characterised by stable demand and long-term structural growth drivers.
Sensor Fonder has now reached the milestone of SEK 6 billion in assets under management. This growth reflects continued confidence from both existing and new investors, as well as from advisers and distributors, combined with stable performance and a clear investment philosophy.
Idun Liv appoints Linnea Moberg as new CEO as the company scales up its operations. She will assume the role following regulatory approval.